Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

false-positive immunofixation results. Furthermore the investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS further.

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

  • 0 views
  • 08 Mar, 2021
  • 1 location
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment …

bortezomib
high dose chemotherapy
velcade
cell transplantation
melphalan
  • 16 views
  • 07 Nov, 2020
  • 7 locations
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

urine, immunofixation positive/negative and MRD-positivity (by NGF). Free light chain (FLC) and CT/PET will be evaluated at time 0. NGF will be done on marrow aspirate at time 0, at 2 months and every 6

daratumumab
cancer
neutrophil count
platelet count
immunofixation
  • 3 views
  • 22 Jan, 2021
  • 1 location
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival …

calcium
serum calcium
cancer
warfarin
heparin
  • 15 views
  • 27 Jan, 2021
  • 1 location
Bendamustine Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be …

corticosteroids
monoclonal protein
rituximab
bendamustine
lymphoma
  • 0 views
  • 04 Aug, 2021
  • 5 locations
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Multiple Myeloma (MM) is a morbid disease which can only be cured with an allogeneic hematopoietic stem cell transplant (HSCT). Approximately 50% of allotransplanted patients will relapse, with a median survival of 5 years. Better approaches to improve disease control at relapse, while decreasing toxicity, are urgently needed. Relapse after …

graft versus host disease
measurable disease
cell transplantation
lenalidomide
bone marrow procedure
  • 31 views
  • 22 Aug, 2021
  • 3 locations
ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy

The study will investigate the stabilization effects of Tafamidis utilizing cardiac imaging cardiac magnetic resonance imaging (CMR). The investigators propose to pursue the following specific aims: Utilize cardiac magnetic resonance to assess stabilization of ATTR after Tafamidis therapy based on extracellular volume mapping. Investigate left ventricular myocardial mass, native T1, …

MRI
tafamidis
cardiac mri
amyloidosis
cardiomyopathy
  • 0 views
  • 02 Feb, 2021
  • 1 location